Peer-reviewed veterinary case report
Oral N-acetyl-d-glucosamine effects on urine in cats with cystitis
By Panchaphanpong, Jinnapat et al.·Published in American journal of veterinary research·2011·Department of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of oral administration of N-acetyl-d-glucosamine on plasma and urine concentrations of glycosaminoglycans in cats with idiopathic cystitis.
- Species:
- cat
Plain-English summary
A group of cats with idiopathic cystitis (IC), which can cause painful urination and frequent trips to the litter box, were given a daily oral supplement called N-acetyl-d-glucosamine (NAG) for 28 days to see if it would help. The results showed that the cats receiving NAG had higher levels of certain substances in their blood that are important for bladder health compared to those who received a placebo. After three weeks of treatment, the NAG group showed significant improvement in these levels, suggesting that this supplement may help manage symptoms of IC in cats.
People also search for: cat idiopathic cystitis treatment · N-acetyl-d-glucosamine for cats · cat urinary health supplements
Abstract
OBJECTIVE: To determine the effects of once-daily oral administration of N-acetyl-d-glucosamine (NAG) on plasma and urine glycosaminoglycan (GAG) concentrations in cats with idiopathic cystitis (IC). ANIMALS: 19 cats with IC and 10 clinically normal cats. PROCEDURES: Cats with IC were randomly assigned to receive 250 mg of NAG in capsule form orally once daily for 28 days (n = 12) or a placebo (capsule containing cellulose) orally once daily for the same period (7). In cats with IC, plasma and urine GAG concentrations and urine creatinine concentration were measured on days 0 (immediately before first dose), 7, 14, 21, 28, and 56. For purposes of comparison, those variables were measured in 10 clinically normal cats on day 0. RESULTS: Mean ± SEM urine GAG-to-creatinine concentration ratios (day 0 data) for cats with IC and clinically normal cats differed significantly (3.11 ± 0.62 μg/mL and 14.23 ± 3.47 μg/mL, respectively). For cats with IC, mean plasma GAG concentration in NAG-treated cats (39.96 ± 5.34 μg/mL) was higher than that in placebo-treated cats (24.20 ± 3.35 μg/mL) on day 21. In the NAG-treated cats, plasma GAG concentration on days 21 (39.96 ± 5.34 μg/mL) and 28 (39.91 ± 6.74 μg/mL) differed significantly from the day 0 concentration (27.46 ± 3.90μg/mL). CONCLUSIONS AND CLINICAL RELEVANCE: Cats with IC have lower urinary GAG-to-creatinine concentration ratios than did clinically normal cats. Administration of NAG (250 mg, PO, q 24 h) significantly increased plasma GAG concentrations in cats with IC after 21 days of treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21627533/